SCHEMBL6468928

SCHEMBL6468928

CC(NC(=O)Cc1cccc(Oc2ccccc2)c1)C(=O)Nc1cnccn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.48
GAA P10253 1/20 0.47
THRB P10828 1/20 0.47
PSMB5 P28074 3/20 0.46
PSMB1 P20618 1/20 0.46
PSMB8 P28062 1/20 0.46
PSMB9 P28065 1/20 0.46
PSMB10 P40306 1/20 0.46
PSMB2 P49721 1/20 0.46
PTGES O14684 1/20 0.44
FFAR1 O14842 1/20 0.43
NTRK1 P04629 1/20 0.43
HTT P42858 1/20 0.43
PRKACA P17612 1/20 0.43
ROCK1 Q13464 1/20 0.43
CYP3A4 P08684 1/20 0.42
RORC P51449 1/20 0.42
NOTUM Q6P988 1/20 0.42
MME P08473 1/20 0.42
ACE P12821 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6469284 0.87 GAA (0.47) FAAHGAATHRBPSMB5HTT
SCHEMBL5784227 0.78 RAF1 (0.56) PSMB5PSMB1PSMB8PSMB9PSMB10
SCHEMBL6468455 0.76 NTRK1 (0.42) GAATHRBPSMB5NTRK1NOTUM
SCHEMBL4063019 0.74 PSMB5 (0.49) PSMB5PSMB1PSMB8PSMB9PSMB10
SCHEMBL6469018 0.74 FAAH (0.47) FAAHPTGESFFAR1PRKACAROCK1
SCHEMBL5041099 0.74 S1PR1 (0.43) PSMB5PSMB1PSMB8PSMB9PSMB10
SCHEMBL5047006 0.72 S1PR1 (0.43) PSMB5PSMB1PSMB8PSMB9PSMB10
SCHEMBL6468835 0.72 MME (0.48) GAAPSMB5PSMB1PSMB8PSMB9
SCHEMBL3636772 0.71 FAAH (0.86) FAAH
SCHEMBL27858347 0.71 KMT2A (0.63) MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders PFIZER, INC. 2005-05-19 US claimed
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders PFIZER, INC. 2005-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders APP, BACE1, SNCA FAAH 2514/4885GAA 186/4885THRB 869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.